Thanks for your thoughts @katy & yes looking very positive.
While PromarkerD is ready to go in EU with Regulatory Approval & what is going on with CKD/DKD patients with COVID-19 (a big link to risk factors for mortality 20-25% of patients who have died had diabetes Type2 in global studies). The risk of not identifying DKD has also increased in multiple studies, especially during lockdowns has been an issue plus the added risk of kidney disease and heart disease in patients following COVID-19 infection that wasn’t present prior.
The risk has been identified & also very recently genetic variation in acutely unwell patients with 5 genetic variations identified, one of them identified in CCR2 which to the best of my knowledge, PIQ have been working with Dimerix on for Kidney Disease trials & now this indication for MCP-1 as a biomarker for testing in the inflammatory response in kidney disease & also in ARDS in COVID-19 & the evidence has just been building. MCP-1 was identified as reduced 39.1% in recent FSGS & DKD trial. PIQ test validation also. I hope this is still the case & would make sense they were doing biomarker work on both FSGS & DKD trials.
I think that the analytics side of PIQ will be a really big thing, clinical trials must be inclusive of all races & ethnicity as there can be genetic differences in response to drugs & vaccines. I think that when we see a bit more data come out on the Pfizer COVID-19 vaccine (approved in the USA for adults 16 years old or greater, but data lacking in Asian & Indian patients), Janssen are very big on racial inclusion & it needs to be that way, because even with male vs female & racial disparities even numbers in eGFR for DKD can be different.
It’s unfortunate that patients were returning false positive HIV results on Australia’s vaccine hope for COVID-19. Also the setback for Sanofi/GSK vaccine.
Pfizer vaccine isn’t perfect either, & now after only a short period, all people who have a history of anaphylaxis to drugs or food have been advised not to have the vaccine until more data is available. That is excluding many millions of people. They did not include people on their clinical trial with severe allergies. It may be to co-factors in the vaccine & 2 out of 80,000 that’s pretty normal, but not if it happens to you.
GLTAH
PIQ Price at posting:
76.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)